Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 4/20 | 0.80 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.80 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.80 |
| ▸ | NAAA | Q02083 | 1/20 | 0.62 |
| ▸ | PRCP | P42785 | 3/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22179378 | 1.00 | GNAI3 (0.80) | GNAI3GNAO1GNAI1NAAAPRCP | |
| SCHEMBL11841856 | 1.00 | GNAI3 (0.80) | GNAI3GNAO1GNAI1NAAAPRCP | |
| SCHEMBL22179098 | 1.00 | GNAI3 (0.80) | GNAI3GNAO1GNAI1NAAAPRCP | |
| SCHEMBL22178782 | 1.00 | GNAI3 (0.80) | GNAI3GNAO1GNAI1NAAAPRCP | |
| SCHEMBL22179371 | 1.00 | GNAI3 (0.80) | GNAI3GNAO1GNAI1NAAAPRCP | |
| SCHEMBL22178791 | 1.00 | GNAI3 (0.80) | GNAI3GNAO1GNAI1NAAAPRCP | |
| SCHEMBL22178856 | 1.00 | GNAI3 (0.80) | GNAI3GNAO1GNAI1NAAAPRCP | |
| SCHEMBL22179122 | 1.00 | GNAI3 (0.80) | GNAI3GNAO1GNAI1NAAAPRCP | |
| Hydrochloric Acid SCHEMBL22160569 | 0.98 | GNAI3 (0.83) | GNAI3GNAO1GNAI1NAAAPRCP | |
| Hydrochloric Acid SCHEMBL22160609 | 0.98 | GNAI3 (0.83) | GNAI3GNAO1GNAI1NAAAPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3445758-B1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | SCRIPPS RESEARCH INST (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | TLR1, TLR4, TLR2 | GNAI3 2266/4885GNAO1 1783/4885GNAI1 1512/4885 |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | TLR1, TLR4, TLR2 | GNAI3 2152/4885GNAO1 1708/4885GNAI1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.